Compare CRAI & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | BLFS |
|---|---|---|
| Founded | 1965 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1998 | 2013 |
| Metric | CRAI | BLFS |
|---|---|---|
| Price | $156.96 | $22.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $245.00 | $32.00 |
| AVG Volume (30 Days) | 116.7K | ★ 325.7K |
| Earning Date | 01-01-0001 | 04-14-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | 25.05 | ★ 71.05 |
| EPS | ★ 6.74 | N/A |
| Revenue | ★ $687,414,000.00 | $82,254,000.00 |
| Revenue This Year | $10.57 | $18.45 |
| Revenue Next Year | $3.66 | $16.27 |
| P/E Ratio | $23.81 | ★ N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $149.96 | $19.15 |
| 52 Week High | $227.29 | $29.57 |
| Indicator | CRAI | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 48.84 |
| Support Level | $149.96 | $20.34 |
| Resistance Level | $195.52 | $26.77 |
| Average True Range (ATR) | 8.58 | 0.96 |
| MACD | -0.50 | 0.16 |
| Stochastic Oscillator | 24.34 | 73.62 |
CRA International Inc is a U.S.-based advisory firm that provides economic, financial, and management consultancy services. The company advises clients on economic and financial issues relating to litigation and regulatory proceedings and helps businesses set important business strategies and solve performance-related issues. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. CRA International generates majority of its revenue from the United States, while it also has its presence in United Kingdom and Other Countries.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.